Study of How Radiotherapy With or Without Chemotherapy Affects Blood Lymphocyte Subsets in Adults with Thoracic Cancers

What this Trial Is About

Researchers are observing changes and the prognostic significance of peripheral blood lymphocyte subsets in patients diagnosed with thoracic cancers, including lung cancer, esophageal squamous cell carcinoma, and thymic epithelial carcinoma. These patients have undergone radiotherapy with or without chemotherapy. The study aims to understand how these treatments may affect the immune cells in the blood and their relationship with patient outcomes. This observational study does not involve assigning treatments but follows patients who receive radiotherapy alone or combined with chemotherapy as part of their care. Researchers will collect and analyze blood samples to monitor lymphocyte subsets before and during treatment. The study is conducted at a single center and includes patients with confirmed thoracic cancers who meet specific clinical and laboratory criteria. Participants will be followed for up to five years to evaluate overall survival and progression-free survival as primary and secondary outcomes. The study involves collecting tumor biopsies before and during treatment, tracking organ function and blood counts, and monitoring patient health status. Data collected will help assess the value of peripheral blood lymphocytes as prognostic markers in thoracic cancer treatment.

Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer